REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell shot aims to tame tough lupus cases
Disease control Recruiting nowThis early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It …
Matched conditions: REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Lupus patients get hope from Cancer-Fighting cell therapy
Disease control Recruiting nowThis early-phase trial is testing a new treatment called GC012F (CD19-BCMA CAR-T cells) for people with severe lupus that hasn't improved with standard medications. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells driving the disease. T…
Matched conditions: REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Lupus patients may get new hope from In-Body cell therapy
Disease control Recruiting nowThis early study tests a new treatment called IASO207 for people with active lupus that hasn't responded to standard therapies. The treatment works by creating special immune cells inside the body to target and calm the overactive immune system. The study will check if it's safe …
Matched conditions: REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immune cell therapy shows promise for Tough-to-Treat lupus
Disease control Recruiting nowThis study tests a new treatment for adults with severe lupus that hasn't improved with standard therapies. Doctors will use a person's own immune cells, modified to target specific lupus-driving cells (CD19 or BCMA), and give them back as a one-time infusion. The goal is to cont…
Matched conditions: REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC